Acupuncture in Chronic Migraine: A Randomized Controlled Trial

NCT ID: NCT01096420

Last Updated: 2013-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to investigate the efficacy and tolerance of acupuncture treatment compared with pharmacologic treatment in patients with chronic migraines.Besides, the investigators tested whether the clinical effects of acupuncture in chronic migraine prophylaxis are mediated by changes of the plasma CGRP (Calcitonin gene-related peptide).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects who completed the prospective baseline periods and meet met the prespecified entry criteria will be randomized into 2 groups: acupuncture treatment, and topiramate treatment group.

Subjects will be allowed to continue taking acute migraine medications for the treatment of breakthrough attacks during the trial, but any migraine preventive medications will be prohibited.

Written informed consent was obtained from all participants before entering the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Chronic Migraine

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

chronic migraine acupuncture Topiramate Randomized trial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

acupuncture

Group Type EXPERIMENTAL

acupuncture

Intervention Type PROCEDURE

Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.

Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).

Sterile disposable and steel needle (3210) were used .

The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi.

topiramate

Group Type ACTIVE_COMPARATOR

topiramate

Intervention Type DRUG

The patients were submitted to the topiramate treatment also for 12 consecutive weeks.

The study phase consists of a 4-week titration and a 8-week maintenance period.

All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).

Study drug was administered daily in equally divided twice daily doses.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acupuncture

Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.

Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).

Sterile disposable and steel needle (3210) were used .

The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi.

Intervention Type PROCEDURE

topiramate

The patients were submitted to the topiramate treatment also for 12 consecutive weeks.

The study phase consists of a 4-week titration and a 8-week maintenance period.

All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).

Study drug was administered daily in equally divided twice daily doses.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 75 years old
* Patients were required to have a diagnosis of chronic migraine with or without medication overuse that satisfied the ICHD-2 criteria during the last 3 months prior to trial entry, with an established migraine history for at least 1 year.

Exclusion Criteria

* Patients did not fulfill the criteria of ≧ 15 days or response to triptans or ergots on at least 8 days in prospective baseline periods .
* The presence of headaches other than chronic migraine (such as another primary chronic headache or any secondary headache).
* Migraine prophylaxis agents during last 3 months including β-blockers, anti-depressants, calcium channel blockers, anti-epileptic agents or cycle-modulating hormonal drugs.
* Migraine onset after age 50 or the age at onset of CM \> 60 years.
* History of hepatic disorder, nephrolithiasis or other severe illness.
* Cognitive impairment interfering with the subject's ability to follow instructions and describe symptoms.
* Prior fearful experience of acupuncture.
* Bleeding diathesis or anticoagulation.
* Pregnant or nursing.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kuang Tien General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chun-pai Yang

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kuang Tien General Hospital

Taichung, Taiwan, Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

References

Explore related publications, articles, or registry entries linked to this study.

Yang CP, Chang MH, Liu PE, Li TC, Hsieh CL, Hwang KL, Chang HH. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia. 2011 Nov;31(15):1510-21. doi: 10.1177/0333102411420585. Epub 2011 Oct 21.

Reference Type DERIVED
PMID: 22019576 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9713

Identifier Type: -

Identifier Source: org_study_id